Mustang Bio, Inc.
Mustang Bio is developing novel immunotherapies based on the ground breaking Chimeric Antigen Receptor (CAR) research of Dr. Stephen Forman and Dr. Christine Browne of City of Hope, an NCI-designated Comprehensive Cancer Center. Mustang was formed to help bring this pioneering CAR research to as many patients as possible. Mustang, through a research agreement with COH, will develop CARs across multiple cancers, including for AML and Brain Cancer. Both of the lead programs are in Phase I clinical development. Mustang believes that harnessing the body’s own immune system to treat cancer is the next generation of cancer care that may prove curative across tumor types that have proved resilient to standard pharmacological and biological treatments. Fortress Biotech owns >50% of Mustang Bio.
For more information, please visit www.mustangbio.com.